# the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma

> **NCT05408221** · PHASE2,PHASE3 · RECRUITING · sponsor: **Shandong New Time Pharmaceutical Co., LTD** · enrollment: 576 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Rulonilimab+Lenvatinib
- **DRUG:** Rulonilimab placebo +Lenvatinib

## Key facts

- **NCT ID:** NCT05408221
- **Lead sponsor:** Shandong New Time Pharmaceutical Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-11
- **Primary completion:** 2025-08-01
- **Final completion:** 2026-08-01
- **Target enrollment:** 576 (ESTIMATED)
- **Last updated:** 2023-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05408221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05408221, "the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05408221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*